DIMA Biotech has been committed to the development and production of proteins and antibodies with a focus on the cancer therapies targets. We provide a one-stop service for the early antibody drugs discovery and accelerate the whole drug development process.

Instead of screening your own antibodies, you can directly get antibodies from the DIMA mAb libraries with verified FC binding data, carry out the in-vitro and in-vivo functional validations, and choose the right molecules for large amount antibody productions, which reduces the risk and time for your research and development.

At present, DIMA has developed B cell seed libraries and the corresponding pilot antibody molecules for around 600+ targets for blood tumor, immune checkpoints and solid tumors. All targets have human-rabbit chimeric antibodies, and 50+ targets have completed humanization antibodies developed by our DiLibrary™ display platform.